APEX is a patient-driven pharmaceutical company which develops and commercializes clinically evaluated psilocybin-derived treatments to tackle the most critical unmet need in depression, anxiety, and PTSD among Veterans and the general public. Our vision is to work with regulators and advocacy groups to expedite our clinical programs and data capture to facilitate broad access.